Latest BPH Stories
SANTA CLARA, Calif., April 23 /PRNewswire/ -- Lumenis Inc., a subsidiary of Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced today at the American Urological Association's (AUA) annual show the introduction of a Holmium Laser Enucleation of the Prostate (HoLEP) training simulator and the PolyScope Disposable Ureteroscope(1), a new flexible scope with enhanced vision and...
-- New product, now available in pharmacies, will provide rapid symptom relief for number one reason men visit a urologist -- CORONA, Calif., April 7 /PRNewswire-FirstCall/ --Watson Pharmaceuticals, Inc.
Supporting men's health awareness by exploring solutions to the most common health problem for men over the age of 60 ROSEMEAD, Calif., March 31 /PRNewswire/ -- The causes and treatments of enlarged prostate will be the focus of a free community seminar on April 2, 2009 at 6:30pm at the Doubletree Hotel in Rosemead.
Supporting men's health awareness by exploring solutions to the most common health problem for men over the age of 60 NEENAH, Wis., March 31 /PRNewswire/ -- The causes and treatments of enlarged prostate will be the focus of a free community seminar on April 2, 2009 at 6:30pm at the Theda Clark Medical Center in Neenah.
SOUTHAMPTON, England, March 24 /PRNewswire/ -- - VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I Dosing Vantia Therapeutics, a company focusing on first-in-class therapies for unmet medical needs, announces further clinical trial progress with its two lead development compounds, VA106483 for nocturia associated with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea.
All amounts are in U.S. dollars QUEBEC CITY, March 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
Development and Commercialization for Cetrorelix Pamoate in Benign Prostatic Hyperplasia BRIDGEWATER, N.J., March 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S.
All amounts are in US dollars QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
QUEBEC CITY, Dec. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce positive new results from the Company's most recent study of NX-1207, its drug in development for benign prostatic hyperplasia (BPH). A total of 67 patients and controls in this multi-center U.S.
- A trick or prank.